PLX - Protalix BioTherapeutics, Inc.
| Previous Close | 0.4549 |
| Open | 0.4500 |
| Bid | 0.4533 x 1100 |
| Ask | 0.4540 x 1100 |
| Day's Range | 0.4500 - 0.4540 |
| 52 Week Range | 0.2700 - 0.8300 |
| Volume | 81,221 |
| Avg. Volume | 261,104 |
| Market Cap | 67.262M |
| Beta (3Y Monthly) | 3.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1790 |
| Earnings Date | Mar 10, 2016 - Mar 14, 2016 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.50 |
- Zacks•8 days ago
Protalix (PLX) Completes Enrollment in Fabry Disease Study
Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.
- GlobeNewswire•9 days ago
Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
CARMIEL, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the completion of enrollment in the phase III BRIGHT clinical trial of pegunigalsidase alfa, or PRX‑102, for the treatment of Fabry disease, via intravenous (IV) infusions of 2 mg/kg administered every 4 weeks. PRX‑102 is the Company’s plant cell-expressed recombinant, PEGylated, cross-linked α‑galactosidase‑A drug candidate. The BRIGHT study is a 12 month, open-label switchover study to assess the safety, efficacy and pharmacokinetics (PK) of pegunigalsidase alfa 2 mg/kg administered every 4 weeks in up to 30 Fabry patients previously treated with an enzyme replacement therapy (ERT): Fabrazyme® or Replagal®. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with stable kidney disease. Patients that matched the criteria were enrolled in the study and switched from their current treatment of intravenous (IV) infusions every 2 weeks to 2 mg/kg of PRX‑102 every 4 weeks for 12 months.
- GlobeNewswire•20 days ago
Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (PLX.TA), or Protalix, and Chiesi Farmaceutici S.p.A, an international research-focused healthcare Group, or Chiesi, today announced that, following a series of meetings and correspondence with the U.S. Food and Drug Administration (FDA), they plan to file a biologics license application, or a BLA, for pegunigalsidase alfa for the treatment of Fabry disease in the first quarter of 2020 via the FDA’s Accelerated Approval pathway.
- Simply Wall St.•26 days ago
Why Przetwórstwo Tworzyw Sztucznych Plast-Box S.A.'s (WSE:PLX) High P/E Ratio Isn't Necessarily A Bad Thing
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it...
- GlobeNewswire•last month
Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
CARMIEL, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA) today announced that Dror Bashan has been appointed to serve as the Company’s new President and Chief Executive Officer, and a director, effective June 30, 2019, replacing Moshe Manor, who is stepping down from those roles for personal reasons. Mr. Manor will assist with the transition and continue to work with the Company on a consultant basis.
- Thomson Reuters StreetEvents•last month
Edited Transcript of PLX earnings conference call or presentation 6-May-19 12:30pm GMT
Q1 2019 Protalix Biotherapeutics Inc Earnings Call
- Simply Wall St.•2 months ago
Przetwórstwo Tworzyw Sztucznych Plast-Box S.A. (WSE:PLX) Delivered A Weaker ROE Than Its Industry
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Zacks•2 months ago
Protalix (PLX) Reports Q1 Loss, Tops Revenue Estimates
Protalix (PLX) delivered earnings and revenue surprises of -66.67% and 2.85%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Protalix: 1Q Earnings Snapshot
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 5 cents. The drug developer posted revenue of $10.4 million in the period. The company's shares closed at 44 cents. A year ...
- GlobeNewswire•2 months ago
Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update
CARMIEL, Israel, May 06, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and.
- Zacks•2 months ago
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.
- Simply Wall St.•2 months ago
Is Protalix BioTherapeutics, Inc.'s (NYSEMKT:PLX) CEO Being Overpaid?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2014 Moshe Manor was appointed CEO of Protalix BioTherapeutics, Inc. (NYSEMKT:PLX). Thi...
- GlobeNewswire•2 months ago
Protalix BioTherapeutics to Hold First Quarter 2019 Financial Results and Corporate Update Conference Call on May 6, 2019
CARMIEL, Israel, April 29, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
- Zacks•3 months ago
Do Options Traders Know Something About Protalix (PLX) Stock We Don't?
Investors need to pay close attention to Protalix (PLX) stock based on the movements in the options market lately.
- GlobeNewswire•3 months ago
Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update
CARMIEL, Israel, March 18, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization.
- ACCESSWIRE•3 months ago
Protalix Biotherapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Protalix Biotherapeutics, Inc. (NYSEMKT: PLX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 18, 2019 ...
- GlobeNewswire•3 months ago
Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call
CARMIEL, Israel, March 13, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
- Simply Wall St.•3 months ago
When Will Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Turn A Profit?
Protalix BioTherapeutics, Inc.'s (NYSEMKT:PLX): Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in IsraelRead More...
- GlobeNewswire•4 months ago
Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019
CARMIEL, Israel, March 06, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
- Benzinga•5 months ago
The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...
- GlobeNewswire•5 months ago
Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
CARMIEL, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that preliminary pharmacokinetic (PK) data from its phase III BRIGHT study of pegunigalsidase alfa, or PRX-102, for the treatment of Fabry disease is the subject of an oral presentation at the 15th Annual WORLDSymposiumTM 2019. The conference is taking place February 4-8, 2019 at the Hyatt Regency Orlando, Orlando, Florida, and the oral presentation is scheduled for Thursday, February 7, 2019 at 8:30 AM ET. PRX-102 is the Company’s plant cell-expressed recombinant, PEGylated, cross-linked α-galactosidase-A drug candidate for the treatment of Fabry disease. The BRIGHT study is a 12-month, open-label switchover study to assess the safety, efficacy and pharmacokinetics of pegunigalsidase alfa 2 mg/kg administered every 4 weeks in up to 30 Fabry patients previously treated with an enzyme replacement therapy (ERT): Fabrazyme® or Replagal®. As of December 23, 2018, 28 patients had been enrolled in the BRIGHT study, and 15 of those patients had completed 9 months of treatment. Samples from these 15 patients underwent pharmacokinetic (PK) evaluation and were tested for the presence of anti-drug antibodies (ADA).
- Benzinga•5 months ago
The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs
The earnings season hasn't panned out well for pharma companies, with Amgen, Inc. (NASDAQ: AMGN ), Novartis AG (NYSE: NVS ) and Illumina, Inc. (NASDAQ: ILMN ) reporting either disappointing results or ...
- GlobeNewswire•5 months ago
New Research: Key Drivers of Growth for Voya Financial, Conduent, Milacron, Altair Engineering, Genesis Healthcare, and Protalix BioTherapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•5 months ago
Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
CARMIEL, Israel, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that the Company will present preliminary pharmacokinetic (PK) data from its phase III BRIGHT study of pegunigalsidase alfa for the treatment of Fabry disease at the 15th Annual WORLDSymposium™ 2019. The conference will take place February 4-8, 2019 at the Hyatt Regency Orlando, Orlando, Florida. Preliminary results of a Phase 3 study,” highlighting PK and safety data will be presented by Mr. Myrl D. Holida, PA, of the University of Iowa Health Care in Iowa City, Iowa, a principal investigator in the Company’s clinical trial of PRX-102 for the treatment of Fabry disease, on Thursday, February 7, 2019 at 8:30 AM ET.
